Country: Canada
Language: English
Source: Health Canada
PRAVASTATIN SODIUM
NU-PHARM INC
C10AA03
PRAVASTATIN
20MG
TABLET
PRAVASTATIN SODIUM 20MG
ORAL
100/500
Prescription
HMG-COA REDUCTASE INHIBITORS
Active ingredient group (AIG) number: 0122563002; AHFS:
CANCELLED POST MARKET
2012-09-04
Page 1 of 42 PRODUCT MONOGRAPH Pr NU-PRAVASTATIN PRAVASTATIN SODIUM 10, 20 AND 40 MG TABLETS LIPID METABOLISM REGULATOR NU-PHARM INC. 1165 CREDITSTONE ROAD, UNIT 2 VAUGHAN, ON DATE OF REVISION: L4K 4N7 MARCH 3, 2011 _CONTROL # 144758 _ Page 2 of 42 TABLE OF CONTENTS PART I: HEALTH PROFESSIONAL INFORMATION....................................................... 3 SUMMARY PRODUCT INFORMATION ............................................................................. 3 INDICATIONS AND CLINICAL USE ................................................................................... 3 CONTRAINDICATIONS ........................................................................................................ 5 WARNINGS AND PRECAUTIONS....................................................................................... 5 ADVERSE REACTIONS....................................................................................................... 10 DRUG INTERACTIONS ....................................................................................................... 15 DOSAGE AND ADMINISTRATION ................................................................................... 17 OVERDOSAGE...................................................................................................................... 18 ACTION AND CLINICAL PHARMACOLOGY.................................................................. 19 STORAGE AND STABILITY............................................................................................... 21 DOSAGE FORMS, COMPOSITION AND PACKAGING .................................................. 21 PART II: SCIENTIFIC INFORMATION ............................................................................. 22 PHARMACEUTICAL INFORMATION............................................................................... 22 CLINICAL TRIALS ............................................................................................................... 23 DETAILED PHARMACOLOGY ..................................... Read the complete document